Immuron Limited (IMRN)

NASDAQ: IMRN · IEX Real-Time Price · USD
2.07
-0.03 (-1.43%)
Dec 7, 2023, 3:56 PM EST - Market closed
-1.43%
Market Cap 13.15M
Revenue (ttm) 1.24M
Net Income (ttm) -2.61M
Shares Out 5.69M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,476
Open 2.06
Previous Close 2.10
Day's Range 2.05 - 2.08
52-Week Range 1.39 - 3.21
Beta 1.24
Analysts n/a
Price Target n/a
Earnings Date Dec 19, 2023

About IMRN

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1994
Employees 6
Stock Exchange NASDAQ
Ticker Symbol IMRN
Full Company Profile

Financial Performance

In 2023, Immuron's revenue was 1.80 million, an increase of 135.85% compared to the previous year's 765,193. Losses were -3.79 million, 32.7% more than in 2022.

Financial numbers in AUD Financial Statements

News

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunt...

3 days ago - GlobeNewsWire

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholder...

9 days ago - GlobeNewsWire

Immuron CEO Steven Lydeamore Investor Webinar Presentation

MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholder...

24 days ago - GlobeNewsWire

Immuron CEO Steven Lydeamore presented at AusBioInvest

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief ...

5 weeks ago - GlobeNewsWire

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the se...

7 weeks ago - GlobeNewsWire

Immuron achieves record quarterly Travelan® sales

Highlights: Record quarterly Travelan® sales of $1,550,240 Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales 130% higher than pre-pandemic period Q1, FY20 sales MELBOURNE, A...

2 months ago - GlobeNewsWire

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Presentation on Wednesday, October 4th at 11:00 PT Melbourne, Australia--(Newsfile Corp. - September 18, 2023) - Immuron Limited (NASDAQ: IMRN), an Australian based and globally integrated biopharmace...

2 months ago - Newsfile Corp

Immuron achieves record monthly Travelan® sales

Highlights: Record monthly Travelan® sales Australian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (A...

3 months ago - GlobeNewsWire

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief ...

3 months ago - GlobeNewsWire

Immuron to present at the Military Health System Research Symposium

MELBOURNE, Australia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it w...

4 months ago - GlobeNewsWire

Immuron Announces First Patients Enrolled in Travelan® Clinical Study

Highlights: First cohort of 30 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced Final 3...

4 months ago - GlobeNewsWire

Immuron CEO, Steven Lydeamore to present at Bioshares

MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief E...

4 months ago - GlobeNewsWire

Immuron Business Update - Ateria Health launches Juvia™ in Australia

Highlights: Ateria has launched Juvia™ containing breakthrough natural ingredient ERME™ in Australia New clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to m...

5 months ago - GlobeNewsWire

Immuron FY23 Sales increase 136% on FY22 Sales

Highlights: Australian FY23 sales of A$1.16 M (478% increase on FY22 sales) USA FY23 Travelan® sales of A$643 k (28% increase on FY22 sales) Global FY23 sales of A$1.80 M (136% increase on FY22 sales)...

5 months ago - GlobeNewsWire

Immuron Chairman Transition

MELBOURNE, Australia, June 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the tran...

5 months ago - GlobeNewsWire

Immuron Business Update: Letter to Shareholders

Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission Recruitment and screening update for Travelan® Controlled Human Infection Model (CHIM) Clinical...

6 months ago - GlobeNewsWire

Immuron Initiates Recruitment of Travelan® Clinical Study

Highlights: Immuron receives approval from U.S. Army Medical Research and Development Command Recruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM) Clin...

6 months ago - GlobeNewsWire

Immuron Limited Announces Participation in the LD Micro Invitational XIII

Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset...

7 months ago - Newsfile Corp

Immuron stock rockets after FDA removes hold on IND of infectious diarrhea treatment

The U.S.-listed shares of Immuron Ltd. IMRN powered up 66.3% toward a one-year high in premarket trading Monday, after the Australia-based biopharmaceutical company said the U.S. Food and Administrati...

7 months ago - Market Watch

Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation

Highlights: U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND application US Naval Medical Research Centre (NMRC) satisfactorily addressed all clin...

7 months ago - GlobeNewsWire

Immuron CEO, Steven Lydeamore to present at Coffee Microcaps

MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercial...

7 months ago - GlobeNewsWire

Immuron Q3 FY23 Business Update Presentation

MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commerci...

8 months ago - GlobeNewsWire

Q3 FY23 Business Update Webinar Notification

MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commerci...

8 months ago - GlobeNewsWire

Immuron Q3 Sales reach 150% of 1H Sales

Highlights:

8 months ago - GlobeNewsWire

Immuron CEO, Steven Lydeamore to host an investor webinar

MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercial...

10 months ago - GlobeNewsWire